Date: 2011-01-19
Type of information:
phase: 3
Announcement: treatment of the first patient
Company: GSK (UK)
Product: zanamivir
Action mechanism:
Disease: influenza
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: GSK has announced that the first patient has received treatment in a pivotal Phase III study of hospitalised patients with influenza which compares intravenous (IV) zanamivir to oral oseltamivir. The primary endpoint of this study is time to clinical response in patients with confirmed influenza. The trial has a target enrolment of 462 patients planned in over 20 countries that take into account flu seasons in the northern and southern hemispheres. The study will take approximately three years.
